Cargando…

No added diagnostic value of non-phosphorylated tau fraction (p-tau(rel)) in CSF as a biomarker for differential dementia diagnosis

BACKGROUND: The Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers Aβ(1–42), t-tau, and p-tau(181) overlap with other diseases. New tau modifications or epitopes, such as the non-phosphorylated tau fraction (p-tau(rel)), may improve differential dementia diagnosis. The goal of this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goossens, Joery, Bjerke, Maria, Struyfs, Hanne, Niemantsverdriet, Ellis, Somers, Charisse, Van den Bossche, Tobi, Van Mossevelde, Sara, De Vil, Bart, Sieben, Anne, Martin, Jean-Jacques, Cras, Patrick, Goeman, Johan, De Deyn, Peter Paul, Van Broeckhoven, Christine, van der Zee, Julie, Engelborghs, Sebastiaan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513364/ https://www.ncbi.nlm.nih.gov/pubmed/28709448 http://dx.doi.org/10.1186/s13195-017-0275-5

Ejemplares similares

Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration
por: Goossens, Joery, et al.
Publicado: (2018)

Cerebrospinal Fluid P-Tau(181P): Biomarker for Improved Differential Dementia Diagnosis
por: Struyfs, Hanne, et al.
Publicado: (2015)

Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and (18)F-FDG-PET imaging
por: Ottoy, Julie, et al.
Publicado: (2019)

The Cerebrospinal Fluid Aβ(1–42)/Aβ(1–40) Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer’s Disease in a Clinical Setting
por: Niemantsverdriet, Ellis, et al.
Publicado: (2017)

Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer’s Disease
por: Niemantsverdriet, Ellis, et al.
Publicado: (2016)

Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects
por: Somers, Charisse, et al.
Publicado: (2019)

Improved Alzheimer’s Disease versus Frontotemporal Lobar Degeneration Differential Diagnosis Combining EEG and Neurochemical Biomarkers: A Pilot Study
por: Laton, Jorne, et al.
Publicado: (2022)

An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer’s disease
por: De Roeck, Arne, et al.
Publicado: (2018)

TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies
por: Goossens, Joery, et al.
Publicado: (2015)

Extended FTLD pedigree segregating a Belgian GRN-null mutation: neuropathological heterogeneity in one family
por: Sieben, Anne, et al.
Publicado: (2018)

The genetics and neuropathology of frontotemporal lobar degeneration
por: Sieben, Anne, et al.
Publicado: (2012)

Alzheimer’s disease CSF biomarkers: clinical indications and rational use
por: Niemantsverdriet, Ellis, et al.
Publicado: (2017)

Patients carrying the mutation p.R406W in MAPT present with non-conforming phenotypic spectrum
por: Gossye, Helena, et al.
Publicado: (2022)

Mutated CTSF in adult-onset neuronal ceroid lipofuscinosis and FTD
por: van der Zee, Julie, et al.
Publicado: (2016)

Phenotypic characteristics of Alzheimer patients carrying an ABCA7 mutation
por: Van den Bossche, Tobi, et al.
Publicado: (2016)

Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort
por: Niemantsverdriet, Ellis, et al.
Publicado: (2018)

Amyloid-β(1–43) cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations
por: Perrone, Federica, et al.
Publicado: (2020)

Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson’s disease
por: Smolders, Stefanie, et al.
Publicado: (2021)

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort
por: Van Mossevelde, Sara, et al.
Publicado: (2016)

Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort
por: Gijselinck, Ilse, et al.
Publicado: (2015)

Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke
por: De Vos, Ann, et al.
Publicado: (2017)

Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains
por: Janssens, Jonathan, et al.
Publicado: (2015)

The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter
por: Gijselinck, I, et al.
Publicado: (2016)

Investigating Tissue-Specific Abnormalities in Alzheimer’s Disease with Multi-Shell Diffusion MRI
por: Giraldo, Diana L., et al.
Publicado: (2022)

Behavioral and Neuropathological Phenotyping of the Tau58/2 and Tau58/4 Transgenic Mouse Models for FTDP-17
por: Van Dam, Debby, et al.
Publicado: (2023)

A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms
por: Verelst, Joke, et al.
Publicado: (2020)

TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort
por: van der Zee, Julie, et al.
Publicado: (2011)

The Use of Biomarkers and Genetic Screening to Diagnose Frontotemporal Dementia: Evidence and Clinical Implications
por: Gossye, Helena, et al.
Publicado: (2019)

Callosal circularity as an early marker for Alzheimer's disease
por: Van Schependom, Jeroen, et al.
Publicado: (2018)

Promoter DNA methylation regulates progranulin expression and is altered in FTLD
por: Banzhaf-Strathmann, Julia, et al.
Publicado: (2013)

Loss of DPP6 in neurodegenerative dementia: a genetic player in the dysfunction of neuronal excitability
por: Cacace, Rita, et al.
Publicado: (2019)

H$^{0}$ --> $\tau^{+}\tau^{-}$ detection at the LHC
por: Bos, Kors, et al.
Publicado: (1990)

Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis
por: Slaets, Sylvie, et al.
Publicado: (2015)

Myoclonus and Cerebellar Ataxia Following COVID‐19
por: Dijkstra, Femke, et al.
Publicado: (2020)

The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer’s Disease
por: De Vos, Ann, et al.
Publicado: (2016)

Serum Daytime Melatonin Levels Reflect Cerebrospinal Fluid Melatonin Levels in Alzheimer’s Disease but Are Not Correlated with Cognitive Decline
por: Nous, Amber, et al.
Publicado: (2021)

Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
por: Fossati, Silvia, et al.
Publicado: (2019)

Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis
por: Bjerke, Maria, et al.
Publicado: (2018)

Tau in serum and CSF during cerebral injury
por: Van Droogenbroeck, P, et al.
Publicado: (1997)

A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer’s disease
por: Verheijen, Jan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_d4ip8oqti4fdvrb2cae9u87sts